Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Ali Ataya

Pulmonary Vascular Med · UF

View

Dr. Naftali Kaminski

Interstitial Lung Disease · Yale College

View

Dr. Auston Stiefer

Interstitial Lung Disease · CU Anschutz Medical Campus

View

Dr. Justin Zhang

Critical Care · UCLA

View

Dr. Panagis Galiatsatos

Critical Care · Johns Hopkins

View

Dr. MeiLan Han

Asthma & COPD · UMHS

View

Dr. Kevin Chung

Critical Care · SeaStar Medical

View

Dr. Diego J. Maselli

Asthma & COPD · UTHSCSA

View

Dr. Amos E. Dodi

Critical Care · MMC

View

Dr. Imre Noth

Interstitial Lung Disease · University of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Preserving Lung Function in Idiopathic Pulmonary Fibrosis

    Jul 9, 2026DOI: 10.1056/nejme2606821EditorialNEJM

    Written by: Darren Taichman, M.D., Ph.D.

    Find these authors on Roon

    DT
    Dr. Darren Taichman
    Pulmonary Vascular Med · UPenn

    Summary

    Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease, with an estimated global yearly incidence of approximately 6 per 100,000 and a prevalence of approximately 18 per 100,000. Patients with IPF have progressive dyspnea that is commonly accompanied by a disabling cough, impaired quality of life, and frequent exacerbations that lead to hospitalization. And the disease is deadly, with a median survival of less than 4 years. Antifibrotic agents (e.g., nintedanib and pirfenidone) slow but do not halt an inexorable decline in lung function, but at the price of substantial — and, for many patients, unacceptable — side . . .
    DTDr. Darren Taichman

    Dr. Darren Taichman

    Pulmonology & Critical Care · Pulmonary Vascular Medicine
    University of Pennsylvania
    darren